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Background/Objectives: Adherence is a major challenge in topical glaucoma therapy,
particularly in an African context. We report a pilot study assessing adherence independently
for the ﬁrst time in an African context.
Subjects/Methods: Participants with newly diagnosed open-angle glaucoma received a
weighed bottle of Lumigan 0.01% with counselling on therapy. The bottles were returned
monthly for renewal and weighed on return to estimate drops taken during the period. Data
collection was for one year with a short compliance questionnaire.
Results: 11 patients participated. 5 (45%) failed to complete one full year of topical therapy.
The overall mean number of drops per eye per day was 1.74 (SD 0.69) for the 6 with one
year of monthly returned bottles and controlled IOPs at each visit. Self-perception of
compliance in these patients was good.
Conclusion: The signs of poor adherence based on both self-report (previous literature), and
in this small-scale study of an objective measure suggest medication may not be the ﬁrst-line
treatment of choice in this environment. Our report does, however, raise the possibility that
those patients who return for repeat prescriptions and review are indeed adhering to their
treatment regimens.
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Introduction
Glaucoma is the world’s second most prevalent blinding condition causing irrever-
sible visual loss.1 The prevalence of primary open-angle glaucoma (POAG) is often
higher in individuals of African descent than in Caucasians2,3. There is now clear
evidence that lowering intraocular pressure (IOP) reduces the rate of progression.4–6
Pressure may be lowered by medical therapy, laser therapy or surgical interven-
tion. The most common ﬁrst-line therapy is medical therapy.7 In high-income
countries, there are well-recognised problems with medical therapy. Firstly adher-
ence is a major challenge.8 Secondly, there are adverse effects, both systemic and
topical.9 In an African context, we have identiﬁed 8 published studies investigating
adherence shown in Table 1.
Two studies looked at the opinions of ophthalmologists, three studies involved
questionnaire to patients who had been on medical therapy for over 6 months. Two
studies were medical record reviews and the ﬁnal study involved focus groups with
patients. Poor adherence was consistently reported. No study had investigated the
validity of the ﬁnding using an alternative assessment we, therefore, designed the
pilot study presented here. We reduced the impact of cost by supplying the drops
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for free and undertaking the work in a local hospital
setting to minimise the challenges of travel to receive
therapeutic supplies.
Methods
This study was undertaken in Innovation Eye Clinic, Kisii,
Kenya. Ethical permission for the trial, of which this is a
component, was given by the Aga Khan University
Faculty of Health Sciences Research Ethics Committee.
This study was conducted in accordance with the
Declaration of Helsinki. The trial was a randomised con-
trolled trial of selective laser trabeculoplasty compared to
medical therapy. It had to be abandoned due to recurrent
challenges maintaining a functional laser machine.
Following written, informed consent to participation in
the study, patients received counselling in glaucoma, the
aims of therapy and drop technique. They were supplied
with a bottle of topical bimatoprost 0.01% to use once a
day in the affected eye(s) and informed that the next bottle
would be supplied free of charge in one months’ time upon
return of the current bottle. All bottles were weighed prior
to being given to patients and weighed again upon return;
the underlying assumption being that the difference in
weights represented the quantity of drug used in therapy.
A short questionnaire on adherence was completed.
Primary Outcome Measure
Three bottles of lumigan 0.01% were weighed and 6.99,
6.99 and 7.00 g. A large sample was not taken since the
weight was taken at point of delivery. Two bottles were
weighed 5 times each with an average variation of 0.003 g
showing the accuracy of the scales. Two bottles had their
plastic covers removed. These weighed 0.155 and 0.15 g.
In view of the potential for variation in this weight, it was
decided to remove the plastic seals prior to weighing and
release of bottles to patients.
One bottle was weighed after each drop, it contained
76 drops. The total weight of drug in the bottle was 2.85g.
Each drop amounted to an average weight of 0.0375 g (SD
0.010).
Questionnaire
Guided by social science expertise (HB) and following
discussion with patients and staff, a simple questionnaire
Table 1 Published Studies Reporting Adherence with Medical Therapy for Glaucoma in Sub-Saharan Africa
Country References Study N Findings
Nigeria [10] In-depth interviews with
ophthalmologists
11
ophthalmologists
Poor adherence. Challenges availability, affordability and
counterfeiting of drugs.
Togo [11] Patient on topical therapy for
6+ months questionnaire
107 patients Adherence perceived good 10%, fair 65%, poor 24%.
Benin [12] Patients on topical therapy
for 1+ years questionnaire
120 patients Adherence estimated as 53%.
Nigeria [13] Ophthalmologist
questionnaire
153
ophthalmologists
78% reported poor adherence with therapy a challenge
Ethiopia [14] Medical record review or
patients on topical therapy
for 6+ months
200 patients 68% non-adherent related to older age, advanced stage of
glaucoma, longer follow-up and ﬁnancial problems (all p<0.05)
Nigeria [15] Focus groups with advanced
glaucoma patients
6 focus groups Cost and forgetfulness main reasons for poor adherence.
Insufﬁcient funds and negative staff attitudes reasons for failing
follow-up
Ghana [16] Medical record review of
patients on therapy for 1+
years
891 patients 9.4% fully adherent. Financial cost of adherence found substantial
for patients.
Ethiopia [17] Patients on topical therapy
for 6+ months questionnaire
359 patients 42.6% fully adherent. Higher education, self-employment and
taking fewer drops all associated with good adherence (p<0.05).
Being a farmer, low income and self-purchasing medicines all
associated with poor adherence (p<0.05).
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was developed translated into Kiswahili and back trans-
lated to ensure consistency. This was then administered to
5 clinic patients taking medical therapy for feedback. The
ﬁrst two questions were retained unaltered in the ﬁnal
version; however, a third open-ended question was added
inviting their view as to why they were not adhering. This
questionnaire was aimed at gaining a basic measure of
self-perceived compliance. The ﬁnal questionnaire in
both English and Kiswahili is shown in Figure 1.
Results
A total of 11 patients participated in the study. Of these 5
(45%) failed to complete one full year of topical therapy
for a variety of reasons. One came back for one further
bottle then said he was “otherwise engaged” and could not
come. One came for bottles for four months then stopped
attending and was seen at 6 months at which stage his non-
adherence was discussed and he was listed for surgery.
One developed itchy red eyes after 6 months on therapy
and defaulted further drops and follow-up from that report.
One returned the ﬁrst bottle and did not attend following
this, it turned out her son had taken her to another hospital;
we do not know the outcome following this. One patient
had no reduction in IOP from the drops and was listed for
trabeculectomy surgery.
From the above, the topical drug failed to lower pres-
sure in 1 (9%) and adverse effects were a component of
non-adherence in 4 (36%).
A total of 6 (55%) completed one year of monthly
follow-up with returned bottles and controlled IOPs at
each visit. The baseline study showed each drop amounted
to an average weight of 0.0375 g (SD 0.010) for Lumigan
0.01%. Using this and the weight of drug removed from
the returned bottles all patients showed consistent adher-
ence. The overall mean number of drops per eye per day
was 1.74 (SD 0.69). Over the eleven months of follow-up,
there was a suggestion of slight tail off in frequency of
drop use in the last two months only (Table 2).
Of importance is that every adherent patient had a
comment in the notes that they were experiencing itching,
fullness or redness of the eyes on the drops. Thus, adher-
ence was strong despite topical side effects. Following the
study 4 remained on topical therapy 2 on Lumigan and two
on t-bet [travoprost 0.004% and Timolol 0.5%] since that
Figure 1 Questionnaire on drug adherence administered to patients.
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is a cheaper drug for them. One patient was lost to follow-
up and the ﬁnal patient had a pressure of 26 on ﬁnal return
and was listed for trabeculectomy.
Of the ﬁve who failed to complete a year on lumigan
therapy, adherence data existed for four. The mean number
of drops per day per eye was 1.69 (SD 0.90). As noted
above, two were listed for surgery because of non-
adherence.
Seven patients completed the questionnaire concerning
compliance. All reported good compliance and found the
drugs easy to use as advised. Two patients reported miss-
ing no drops and the remainder reported missing 1–3 doses
per week.
Discussion
We recognise that this pilot study is small and thus prone to
potential bias. None-the-less the ﬁndings do present some
interesting insights. Our ﬁnding of 1/11 (9% (95% CI
1–40%)) with poor response to bimatoprost is in keeping
with Sherwood et al who reported 25% (95% CI 21–29%)
failing to have a pressure drop to 18mmHg or lower.18 The
ﬁnding of non-adherence in 4/11 (36% (95% CI 14–65%)) is
lower than several of the previous reports (Table 1). There are
some factors that may explain the improved adherence in our
study. Firstly the patients had consented to participate in a
study hence were a selected population. Secondly, there was
no charge for the therapy. Thirdly there was monthly contact
with the patients which may contribute to adherence by
reinforcement of the therapeutic message. Reports of non-
adherence are hugely variable not least because of very
different methods of assessing adherence.20 In high-income
settings, comparable measures generally suggest levels of
non-adherence between 10% and 20%.8
To our knowledge, this is the ﬁrst report in a sub-
Saharan population attempting to validate attendance and
reported adherence by an alternative assessment of drop
use. Our ﬁndings suggest that those who attend and
receive regular bottles, take the drops as prescribed. The
use of an unobtrusive medication monitor is regarded as
the “gold standard” in measuring adherence. Such a device
was not available to us hence we used the bottle weight
before and after use. Male gender, poor knowledge of the
disease and complex dose frequencies are deﬁnite risk
factors of poor compliance.20 Our patients had received
counselling in the disease and the once daily dosage regi-
men is the least complex possible. These may have con-
tributed to the high adherence we found.
Establishing the use of drops does not, of course, mean
the drops are entering the eye. Davis et al reviewed the
literature on drop instillation and found reports suggest
6.8–37.3% of patients miss the eye with the drop.21
None-the-less our patients had a reduction in pressure
implying the active ingredient was reaching their eye; at
least on the days they were assessed.
All of our patients mentioned redness or irritation in
the eyes at some stage during the study (recoded in the
notes). This is recognised as a common topical side effect
of bimatoprost, Parish et al reporting 35% with this symp-
tom after 12 weeks therapy.19 It is of note that, despite
these symptoms, our adherent patients persisted with their
medication. We believe this may reﬂect the counselling
they received in the disease and its treatment.
The questionnaire was informative in illustrating that
patient-reported compliance is in agreement with the
weight results of drops taken.
The signs of poor adherence based on both self-report
(previous literature Table 1), and in this small-scale study
of an objective measure, suggest medication may not be
the ﬁrst-line treatment of choice in this environment. Our
report does, however, raise the possibility that those
patients who return for repeat prescriptions and review
are indeed adhering to their treatment regimens.
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Table 2 Average Number of Drops Used per Day by 6 Patients on
Topical Glaucoma Therapy Returning Weighed Bottles Monthly
Month Average Drops Used per Day
First 1.67
Second 1.61
Third 1.90
Fourth 1.77
Fifth 1.60
Sixth 1.63
Seventh 1.52
Eighth 1.77
Ninth 1.64
Tenth 1.16
Eleventh 1.23
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